NCT00756340View on ClinicalTrials.gov

A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Recurrent or Refractory Solid TumorsCNS Malignancies
Interventions
DRUG

Bevacizumab

"* Bevacizumab IV every 2 weeks~* Dose Level 0- 8 mg/kg~* Dose Level 1 (starting dose)- 10 mg/kg~* Dose Level 2- 10 mg/kg"

DRUG

Everolimus

"* Everolimus~* Dose Level 0- 4 mg/m2~* Dose level 1 (starting dose)- 4 mg/m2~* Dose Level 2- 5 mg/m2"

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

St. Jude Children's Research Hospital

OTHER